ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "antiphospholipid syndrome"

  • Abstract Number: 0839 • ACR Convergence 2024

    Comprehensive Single-cell Analysis Reveals Interferon Pathway Activation and Aberrant B Cell Dynamics in APS Autoimmunity

    Haoyu Pan, Xiaohan Wei, Jinyi Qian, Shuyi Yu, Zhixia Yang, Zetao Ding, Chengde Yang and Hui Shi, Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic)

    Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized with the presence of pathogenic antiphospholipid antibodies (aPL) by autoreactive B cells. However, it remains…
  • Abstract Number: 0103 • ACR Convergence 2024

    CD10highLow-Density Granulocytes Is a Potential Marker of Disease Activity in Antiphospholipid Syndrome

    chun Li, Peking University People's Hospital, Beijing, China

    Background/Purpose: To investigate the relationship between CD10highLow-Density Granulocytes (LDG) and disease activity in antiphospholipid syndrome(APS).Methods: This study included 99 patients with APS who were treated…
  • Abstract Number: 0119 • ACR Convergence 2024

    Clinical and Serological Distinctions and Evolutionary Predictors in Antiphospholipid Syndrome and Systemic Lupus Erythematosus: A Multicenter Cohort Analysis

    Basant Elnady1, Ziyad Alakkas2, Sultana Abdulaziz3, Hussain Halabi4, Ahmed A. G. Ibrahim5, Hoda E. Draz5, Mohammed Attar6, Hassan Daghasi7, Abeer Alhalwani8, Reman Shaker9 and Ghadeer Maher Elsheikh10, 1Al Hada Forces Hospital, Rheumatology Department, Taif, Saudi Arabia, 2King Faisal Medical Complex, Taif, Saudi Arabia, 3King Fahad Hospital, Jeddah, Saudi Arabia, 4King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia, 5Benha University, Benha, Egypt, 6al hada armed forces hospital, Taif, Saudi Arabia, 7Alhada military hospital, Taif, Saudi Arabia, 8East Jeddah hospital, Jeddah, Saudi Arabia, 9King Faisal Specialist Hospital and Research centre, Jeddah, Saudi Arabia, 10Menoufia University, Menoufia, Egypt

    Background/Purpose: Antiphospholipid syndrome (APS) is closely linked with Systemic Lupus erythematosus (SLE) and can influence patient outcomes. The interplay between APS and SLE, including the evolution…
  • Abstract Number: 0840 • ACR Convergence 2024

    The Platelet Adenosinergic Axis as a Novel Therapeutic Target for Thrombotic APS

    NaveenKumar Somanathapura K1, Thalia Newman2, Srilakshmi Yalavarthi1, Bruna Mazetto Fonseca1, Kaitlyn Sabb1, Katarina Kmetova3, Emily Chong1, Caroline Ranger1, Cyrus Sarosh4, Jacqueline Madison1, Ajay Tambralli1, Jordan Schaefer1, Michael Holinstat1, Yu Zuo1 and Jason Knight1, 1University of Michigan, Ann arbor, MI, 2University of Michigan, Ann Arbor, MI, 3Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, 4University of Michigan, Temperance, MI

    Background/Purpose: How to most effectively inhibit antiphospholipid antibodies (aPL)-mediated platelet activation remains incompletely understood. CD73 is an ectoenzyme expressed on the platelet surface that generates…
  • Abstract Number: 0104 • ACR Convergence 2023

    Cluster Analysis of Antiphospholipid Antibodies Associated Adverse Pregnancy Outcome Patients: Based on a 13-year Longitudinal Cohort Study

    Yin Long1, Jiuliang zhao2, Mengtao Li2, Xinping Tian2 and xiaofeng Zeng3, 1Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, 2Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Antiphospholipid antibodies (aPLs) play a pivotal role in the etiology of adverse pregnancy outcomes (APOs). (1) Women with persistently aPLs positivity present heterogeneous clinical…
  • Abstract Number: 1208 • ACR Convergence 2023

    Investigating the Experiences of Patients Living with Antiphospholipid Antibodies: A Qualitative Study

    Francesca Cardwell1, Alexandra Kobza2, Susan Elliott1, paul Gibson2, Nancy Soliman2, leslie skeith2, Ann Clarke3 and Megan R.W. Barber2, 1University of Waterloo, Waterloo, ON, Canada, 2University of Calgary, Calgary, AB, Canada, 3University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada

    Background/Purpose: Substantial morbidity and mortality affect those with aPLs and APS, yet the patient experience remains poorly understood. This research investigated patient experiences of aPL/APS…
  • Abstract Number: 0105 • ACR Convergence 2023

    Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis

    Yin Long1, Jiuliang zhao2, Mengtao Li2 and Xiaofeng Zeng2, 1Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, 2Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder characterized by the presence of pathogenic autoantibodies. The key immune cell subsets change in PAPS patients…
  • Abstract Number: 1467 • ACR Convergence 2023

    Antiphospholipid Antibodies and the Risk of Diffuse Alveolar Hemorrhage in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

    Mariana Gonzalez-Trevino1, Jeffrey Yang2, Larry J. Prokop3, Gabriel Figueroa-Parra1 and Ali Duarte-Garcia4, 1Division of Rheumatology, Mayo Clinic, Rochester, MN, 2Department of Internal Medicine, Mayo Clinic, Rochester, MN, 3Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, 4Mayo Clinic, Rochester, MN

    Background/Purpose: Diffuse alveolar hemorrhage (DAH) is one of the most devastating complications of SLE. The exact pathogenesis leading to DAH in SLE is not well…
  • Abstract Number: 0106 • ACR Convergence 2023

    Positive Antiphospholipid Antibodies Are Associated with a Higher Risk of Cerebral Microbleeds

    Junna Ye1, Yijun You2, Zhuochao Zhou2, Fan wang2, Jingyi Wu2 and Chengde Yang2, 1Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, 2Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Background/Purpose: Persistent presence of antiphospholipid antibodies (aPLs) are important thrombosis-related laboratory parameters, as well as an indication of anticoagulation use which usually cause higher bleeding…
  • Abstract Number: 1603 • ACR Convergence 2023

    Infection-Associated Antiphospholipid Antibodies and Their Potential Role in Sepsis Outcomes

    Katarina Kmetova, Emily Chong, NaveenKumar K. Somanathapura, Sherwin Navaz, Lyndsay Kluge, Srilakshmi Yalavarthi, Jason Knight, Michael Maile and Yu Zuo, University of Michigan, Ann Arbor, MI

    Background/Purpose: Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia characterized by circulating antiphospholipid antibodies (aPL). While the association between aPL and infection has long been…
  • Abstract Number: 0107 • ACR Convergence 2023

    Impact of Antiphospholipid Syndrome on Mortality of Hospitalized Ischemic Stroke Patients: A Retrospective Analysis of the National Inpatient Sample Database 2020

    Sami Rabah, Lincoln Medical Center, New York, NY

    Background/Purpose: Antiphospholipid syndrome (APS) is recognized for its association with an elevated risk of ischemic strokes and other thromboembolic events. This study aims to compare…
  • Abstract Number: 1604 • ACR Convergence 2023

    First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Jonathan Thaler1, Yasaman Ahmadzadeh2, Danieli Andrade3, leslie skeith4, Maria Tektonidou5, Savino Sciascia6, Vittorio Pengo7, Jose Pardos-Gea8, Guillermo Ruiz-Irastorza9, Chary Lopez-Pedrera10, H Michael Belmont11, Kello Nina12, Paul R. Fortin13, Denis WAHL14, Maria Gerosa15, Guilherme De Jesús16, Zhuoli Zhang17, Tatsuya Atsuma18, Maria Efthymiou19, D. Ware Branch20, Laura Andreoli21, Esther Rodriguez almaraz22, Michelle Petri23, Giulia Pazzola24, Ricard Cervera25, Bahar Artim Esen26, Hui Shi27, Jason Knight27, Guillermo Pons-Estel28, Rohan Willis29, Ali Duarte-Garcia30, Maria Laura Bertolaccini31, Hannah Cohen32, Doruk Erkan1 and On Behalf Of APS ACTION33, 1Hospital for Special Surgery, New York, NY, 2Roger Williams Medical Center, Providence, RI, 3University of São Paulo, São Paulo, Brazil, 4University of Calgary, Calgary, AB, Canada, 5Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, 6University of Turin, Torino, Italy, 7Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, 8Vall d'Hebron University Hospital, Barcelona, Spain, 9Hospital Universitario Cruces, Barakaldo, Spain, 10IMIBIC - Reina Sofia Hospital, Córdoba, Spain, 11NYU School of Medicine, New York, NY, 12Northwell Health, Brooklyn, NY, 13Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, 14University of Lorraine, Nancy, France, 15University of Milan, Milano, Italy, 16Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 17Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, 18Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, 19University College London, London, United Kingdom, 20University of Utah, Salt Lake City, UT, 21University of Brescia, Brescia, Italy, 22Hospital Universitario 12 de Octubre, Madrid, Spain, 23Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 24Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, 25Hospital Clínic de Barcelona, Barcelona, Spain, 26Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 27University of Michigan, Ann Arbor, MI, 28CREAR, Rosario, Argentina, 29University of Texas Medical Branch, Galveston, TX, 30Mayo Clinic, Rochester, MN, 31King's College London, London, United Kingdom, 32University College London Hospitals NHS Foundation Trust, London, United Kingdom, 33on behalf of APS ACTION, New York, NY

    Background/Purpose: The APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with or…
  • Abstract Number: 0108 • ACR Convergence 2023

    Decoding Antiphospholipid Syndrome Laboratory Test Outcomes in a Large Multicenter Electronic Health Record Database

    Emily Balczewski, Wenying Liang, Amala Ambati, Yu Zuo, Karandeep Singh and Jason Knight, University of Michigan, Ann Arbor, MI

    Background/Purpose: Electronic health record (EHR) data provide an inexpensive, information-rich tool to study rare diseases like antiphospholipid syndrome (APS). Many such studies rely on structured…
  • Abstract Number: 1605 • ACR Convergence 2023

    Complement Activation as a Marker of Thrombosis Risk in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Cecile Yelnik1, Shruti Chaturvedi2, Julien Labreuche1, Xiang-Zuo Pan3, H Michael Belmont4, Kello Nina5, Paul R. Fortin6, D. Ware Branch7, Yu Zuo8, Rohan Willis9, Robert Brodsky10, Jane Salmon11, Maria Laura Bertolaccini12, Hannah Cohen13, Michelle Petri14, Doruk Erkan11 and On Behalf Of APS ACTION15, 1University of Lille, Lille, France, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3John Hopkins University, Baltimore, MD, 4NYU School of Medicine, New York, NY, 5Northwell Health, Brooklyn, NY, 6Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, 7University of Utah, Salt Lake City, UT, 8University of Michigan, Ann Arbor, MI, 9University of Texas Medical Branch, Galveston, TX, 10Johns Hopkins University, Baltimore, MD, 11Hospital for Special Surgery, New York, NY, 12King's College London, London, United Kingdom, 13University College London Hospitals NHS Foundation Trust, London, United Kingdom, 14Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 15on behalf of APS ACTION, New York, NY

    Background/Purpose: Recent studies implicate complement activation in the pathophysiology of antiphospholipid syndrome (APS), especially in patients with severe manifestations, such as catastrophic APS (CAPS). This…
  • Abstract Number: 0109 • ACR Convergence 2023

    Persistent Prothrombotic Activation of Platelet Pannexin 1 Channels in Antiphospholipid Syndrome

    Bruna Mazetto, NaveenKumar Somanathapura, Claire Hoy, Christine Rysenga, Srilakshmi Yalavarthi, Cyrus Sarosh, Caroline Ranger, Katarina Kmetova, Jacqueline Madison, Yu Zuo and Jason Knight, University of Michigan, Ann Arbor, MI

    Background/Purpose: Inappropriately amplified inflammatory responses are hallmarks of many diseases, with extracellular ATP often playing a central role in the orchestration of inflammation. Regulated cellular…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology